At a glance
ClinicalIndex Comparison Record- ✓Newly diagnosed ALL excluding mature B-cell ALL (surface Ig positive)
- ✓Patients with overt CNS or testicular disease are eligible
- ✓Age greater than 1 year and less than 29.99 years
- ✓Adequate organ function required
- ✕Medical, psychological, or psychiatric problems likely to compromise ability to tolerate intensive therapy
- ✕Significant organ dysfunction not attributable to ALL: cardiac ejection fraction <40%, total bilirubin >2, or serum creatinine >2
- ✕Clinically significant congestive heart failure
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating aminopterin, L-asparaginase, and 10 other interventions for Acute Lymphocytic Leukemia. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for relapse of their leukemia.
Study Details
Timeline
Interventions
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation